You are here

  • Home
  • Archive
  • Volume 11, Issue 6
  • First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial

 

Online download statistics by month:

Online download statistics by month: June 2023 to July 2025

AbstractFullPdf
Jun 2023476478116
Jul 202317917987
Aug 202315515754
Sep 202311111233
Oct 2023828327
Nov 2023989823
Dec 2023697029
Jan 2024626344
Feb 2024585838
Mar 2024656550
Apr 2024434339
May 202422722627
Jun 2024484930
Jul 2024373717
Aug 20245146112
Sep 2024313115
Oct 2024404026
Nov 2024414228
Dec 2024636528
Jan 2025525220
Feb 2025797920
Mar 2025434320
Apr 2025727232
May 2025373825
Jun 2025202015
Jul 2025110
Total22402247955